Falanga A, Alessio M G, Donati M B, Barbui T
Istituto di Ricerche Farmacologiche Mario Negri, Milano.
Blood. 1988 Apr;71(4):870-5.
To verify whether cancer procoagulant (CP), a cysteine proteinase procoagulant distinct from tissue factor (TF), is associated with leukemic cells, we assayed the procoagulant activity of blast cell extracts from 26 patients with different cytological subtypes of acute nonlymphoid leukemia (ANLL) according to the French-American-British classification. All the samples except two shortened the recalcification time of normal human plasma, the effect being significantly greater in the M3 subgroup. The two criteria used to distinguish between CP and TF, independence from factor VII in initiating blood coagulation and sensitivity to cysteine-proteinase inhibitors, were positive in 19 samples from M1, M2, M3, and M4 cytological subtypes. None of the M5 samples fulfilled these criteria. In addition, M1, M2, M3, and M4 samples immunoreacted with an anti-CP goat polyclonal antibody on an Ouchterlony immunodiffusion plate. This study provides the first evidence for a procoagulant other than TF that is associated with leukemic cells.
为了验证癌促凝素（CP），一种不同于组织因子（TF）的半胱氨酸蛋白酶促凝剂，是否与白血病细胞有关，我们根据法美英分类法，对26例不同细胞亚型的急性非淋巴细胞白血病（ANLL）患者的原始细胞提取物的促凝活性进行了测定。除两例外，所有样本均缩短了正常人血浆的复钙时间，在M3亚组中这种作用明显更强。用于区分CP和TF的两个标准，即启动血液凝固时不依赖因子VII以及对半胱氨酸蛋白酶抑制剂敏感，在来自M1、M2、M3和M4细胞亚型的19个样本中呈阳性。M5样本均不符合这些标准。此外，M1、M2、M3和M4样本在Ouchterlony免疫扩散板上与抗CP山羊多克隆抗体发生免疫反应。本研究首次证明了除TF外，还有一种促凝剂与白血病细胞有关。
